

Subject Index

A

- Aclacinomycin**, and 7-con-O-methylnoganol (7-OMEN), failure to decrease cardiac guanylate cyclase activity, 1127
- ACNU** (3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea), distribution, excretion, and metabolism of, in rats and mice after iv administration, 575
- 4'-(9-Acridinylamino)methanesulfon-m-anisidide** *see* AMSA
- Actinomycin D**, combined with vincristine and cyclophosphamide followed by doxorubicin and methotrexate in the treatment of advanced sarcoma, 689
- Adenocarcinoma** *see* Cancer, adenocarcinoma
- Adenosine**, selective protection of cells from 6-thioguanine and 6-mercaptopurine by: biochemical approaches to the enhancement of antitumor drug selectivity, 1347
- Adrenal cortical cancer** *see* Cancer, adrenal cortical
- Adriamycin (doxorubicin)**
and CCNU, compared to CCNU, doxorubicin, vincristine, and procarbazine in the treatment of small cell bronchogenic cancer, 997
and *cis*-diamminedichloroplatinum(II), sequential combination chemotherapy with vinblastine and bleomycin in disseminated nonseminomatous testicular cancer, 599
combined with bleomycin, methotrexate, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717
combined with *cis*-diamminedichloroplatinum(II) and *Corynebacterium parvum* in the treatment of non-small cell lung cancer, 1367
combined with cyclophosphamide and bleomycin, in the treatment of metastatic transitional cell carcinoma of the urinary tract, 1001
combined with cyclophosphamide and *cis*-diamminedichloroplatinum(II) (CAP) versus pyrazofurin, randomized trial: phase II study of advanced sarcoma, 655
combined with cyclophosphamide and *cis*-diamminedichloroplatinum(II), lack of clinical therapeutic synergism between, in metastatic human colorectal carcinoma, 311
combined with cyclophosphamide and 5-FU in the treatment of carcinoma of the cervix or vagina, 549
combined with cyclophosphamide and high-dose methotrexate with leucovorin rescue in the treatment of measurable primary or metastatic osteosarcoma, 11
combined with cyclophosphamide in the treatment of advanced recurrent squamous cell carcinoma, 1363
combined with cyclophosphamide, vincristine, and DTIC (CYVADIC) in the treatment of advanced sarcomas, 93
combined with cyclophosphamide, vincristine, and prednisone (CHOP) in the treatment of advanced diffuse histiocytic lymphoma, without maintenance therapy, 649
combined with 5-FU, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157
combined with 5-FU, phase II study of, in the treatment of transitional cell carcinoma of the urinary tract, 161
combined with ifosfamide in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study, 869
combined with melphalan and vincristine in the treatment of advanced breast cancer, 1015
combined with ricin in the treatment of L1210 mouse leukemia, 1375
combined with triazinate, cyclophosphamide, and *cis*-diamminedichloroplatinum(II), phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925
combined with vincristine and cyclophosphamide and either levamisole immunotherapy or placebo in the treatment of advanced breast cancer, 65
combined with vincristine, bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371
combined with VM-26, bleomycin, and prednisone as a secondary treatment of malignant lymphoma, 335
combined with VP-16-213, cyclophosphamide, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135
distribution of, in mice under conditions of local hyperthermia which improve systemic drug therapy, 203
early phase pharmacokinetics of, in plasma of cancer patients during single- or multiple-drug therapy, 845
effect of, on the cell kinetics of 13762 rat mammary tumors and implications for therapy, 293
evaluation of vitamin E and selenium protection against chronic doxorubicin toxicity in rabbits, 315
given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity, 47
intra-arterial infusion of, review of responses, 31
and methotrexate, given after combination of vincris-

tine, actinomycin D, and cyclophosphamide in the treatment of advanced sarcoma, 689
 neurotoxicity of, in rats: a low-dose effect, 257
 randomized comparison of two combination chemotherapy regimens containing, in patients with metastatic breast cancer: a Western Cancer Study Group trial, 981
 studies on the comparative distribution and biliary excretion of, with 4'-epi-doxorubicin, in mice and rats, 897

AMSA

acute ventricular fibrillation and death during infusion of, 356
 multiple ventricular extrasystoles following administration of, 358
 phase I evaluation of, by a weekly iv dose schedule, 53
 phase II evaluation of, in the treatment of advanced colorectal carcinoma, 1149
 phase II evaluation of, in the treatment of metastatic lung cancer, 1383
 phase II evaluation of, in the treatment of non-small cell lung cancer, 345
 phase II study of, in the treatment of advanced sarcoma, 1129
 phase II trial of, in the treatment of advanced non-Hodgkin's lymphoma, 1157
 phase II trial of, in the treatment of metastatic hypernephroma, 183
 phase II trial of, in the treatment of metastatic renal cell carcinoma, 1009
 preclinical toxicologic evaluation of, in mice, dogs, and monkeys, 855

AD 32 (N-trifluoroacetyl Adriamycin-14-valerate), possible relevance of AD 41 in the antitumoral activity of, in tumor-bearing mice: pharmacokinetic evidence, 873

AD 41 (N-trifluoroacetyl Adriamycin), possible relevance of, in the antitumoral activity of AD 32 in tumor-bearing mice: pharmacokinetic evidence, 873

Adenosine deaminase, distribution and inhibition of, in tissues of man, rat, and mouse, 629

Adverse effects, animals

effect of gentamicin and irradiation on the toxicity of high-dose methotrexate in rats, 989
 evaluation of vitamin E and selenium protection against chronic doxorubicin toxicity in rabbits, 315
 neurotoxicity of doxorubicin in rats: a low-dose effect, 257
 selective inhibition of the nephrotoxicity of *cis*-diamminedichloroplatinum(II) by WR-2721 without altering its antitumor properties, 57
 toxicity of spiropregnenin in mice and dogs after iv or im administration, 1207

Adverse effects, man

acute ventricular fibrillation and death during infusion of AMSA, 356
 doxorubicin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity, 47
 anaphylaxis due to oral melphalan, 731
 augmentation of vincristine neurotoxicity by irradiation of peripheral nerves, 963

avascular necrosis of the femoral head: association with adjuvant chemotherapy for breast carcinoma, 361
 cardiomyopathy in adults after combination doxorubicin and DTIC, 353

cellulitis and fibrosis due to *cis*-diamminedichloroplatinum(II) infiltration, 1162

changes in hair pigmentation associated with cancer chemotherapy, 193

chemotherapy-induced emesis, double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on, 219

cholestatic jaundice associated with chlorozotocin, 1235
 clinical pharmacologic effects of thymidine plus 5-FU, 1169

coronary artery disease after treatment with bleomycin and vinblastine, 1159

early detection of lung toxicity after bleomycin therapy, 732

failure of aclacinomycin and 7-con-O-methylnogaro (7-OMEN) to decrease cardiac guanylate cyclase activity, 1127

fatal hepatic necrosis after high-dose chemotherapy following haloalkane anesthesia, 1023

fatal pulmonary bleomycin toxicity in *cis*-diamminedichloroplatinum(II)-induced acute renal failure, 921

hepatotoxicity of hycanthone in patients with metastatic breast cancer, 929

lactic acidosis associated with metastatic breast carcinoma, 1283

leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue, 1261

multiple ventricular extrasystoles following administration of AMSA, 358

photosensitivity reaction following DTIC administration: report of two cases, 725

respiratory dyskinesia associated with hexamethylmelamine, 355

severe skin necrosis produced by piperazinedione extravasation, 1392

skin rashes associated with the administration of the 2-nitroimidazole, misonidazole, 263

vincristine-induced orthostatic hypotension: a prospective clinical study, 359

3-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea *see* ACNU

Amygdalin *see* Laetrile

Anaphylaxis *see* Adverse effects, man

L-Asparaginase

combined with 5-FU, adriamycin, cyclophosphamide, methotrexate, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157

and methotrexate, sequential combination of, in the treatment of refractory acute leukemia, 939

phase II study of, in the treatment of pancreatic carcinoma, 1359

B

Baker's antifol *see also* Triazinate

combined with 5-FU and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group study (protocol 7764), 247

phase II trial of, in the treatment of metastatic renal cell carcinoma: a Southwest Oncology Group study, 1387

BAMP (bleomycin, doxorubicin, methotrexate, and *cis*-diamminedichloroplatinum(II)), in the treatment of non-small cell bronchogenic carcinoma, 717

Benzaldehyde, antitumor activity of, 21

Bladder cancer *see* Cancer, bladder

Bleomycin

- alone or combined with mitomycin C in the treatment of advanced or recurrent squamous cell carcinoma of the vulva, 639
- combined with *cis*-diamminedichloroplatinum(II) and vinblastine in the treatment of mediastinal germ-cell tumors: complete remission of, 319
- combined with cyclophosphamide and doxorubicin, in the treatment of metastatic transitional cell carcinoma of the urinary tract, 1001
- combined with doxorubicin, methotrexate, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717
- combined with mitomycin C in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study, 1139
- combined with vinblastine and followed sequentially by *cis*-diamminedichloroplatinum(II), actinomycin D, and vincristine in the treatment of metastatic testicular cancer, 553
- combined with vinblastine, coronary artery disease after treatment with, 1159
- combined with vinblastine in the treatment of metastatic melanoma, 133
- combined with vincristine and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma, 943
- combined with vincristine, doxorubicin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371
- combined with vincristine, mitomycin C, and *cis*-diamminedichloroplatinum(II) (BOMP) in the treatment of advanced cervical cancer, 1005
- combined with VM-26, doxorubicin, and prednisone as a secondary treatment of malignant lymphoma, 335
- early detection of lung toxicity after therapy with, 732
- epidermal cell kinetics in hairless mice after: perturbations after multiple doses, 1039
- intermittent, combined with vinblastine and single-dose *cis*-diamminedichloroplatinum(II) in the management of stage III testicular cancer, 331
- intra-arterial infusion of, review of responses, 31
- relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomyacin A, 659
- and vinblastine, sequential combination chemotherapy with doxorubicin and *cis*-diamminedichloroplatinum(II) in disseminated nonseminomatous testicular cancer, 599

B16 melanoma *see* Tumor systems, animals

BOMP (bleomycin, vincristine, mitomycin C, and *cis*-diamminedichloroplatinum(II)), in the treatment of advanced cervical cancer, 1005

Brain cancer *see* Cancer, brain

Breast cancer *see* Cancer, breast

Bronchogenic carcinoma *see* Cancer, lung

C

Caffeine, combined with chlorpromazine and methyl-CCNU in the treatment of disseminated melanoma, 151

CAMP (CCNU, melphalan, methotrexate, and prednisone), versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635

Cancer *see also* Leukemia

- adenocarcinoma, advanced endometrial, tamoxifen in the treatment of, 805

- adrenal cortical, cytotoxic chemotherapy in the treatment of, 909

- bladder, low-grade, low-stage transitional cell, phase I-II study of mitomycin C topical therapy in the treatment of: an interim report, 225

- brain

- evaluation of agents (doxorubicin, bleomycin, dianhydrogalactitol, VM-26, epodol, 5-FU, DTIC, BIC, methotrexate, mithramycin, mechlorethamine, BCNU, CCNU, methyl-CCNU, procarbazine, thioTEPA, vincristine, bromouridine, hydroxyurea, metronidazole, and misonidazole) in current use for phase II and III trials, 1179

- malignant tumor, modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of, 237

- breast

- advanced, CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of, in postmenopausal women, 635

- advanced, combination of levamisole immunotherapy and polychemotherapy in the treatment of, 65

- advanced, danazol in the treatment of, 1073

- advanced, male, use of tamoxifen in, 801

- advanced, melphalan, doxorubicin, and vincristine in the treatment of, 1015

- advanced, phase II evaluation of vindesine in the treatment of, 693

- advanced, tamoxifen or fluoxymesterone in the treatment of: a controlled clinical trial, 117

- avascular necrosis of the femoral head: association with adjuvant chemotherapy for, 361

- clinical pharmacology of tamoxifen in patients with: comparison of traditional and loading-dose schedules, 765

- comparisons of cooperative group evaluation criteria for multiple-drug therapy for, 507

- initial clinical study with PALA in the treatment of, 617

- metastatic, chemoimmunotherapy for, with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine, 157
- metastatic, hepatotoxicity of hycanthone in patients with, 929
- metastatic, lactic acidosis associated with, 1283
- metastatic, phase II trial of 6-thioguanine in the treatment of, 191
- metastatic, randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with: a Western Cancer Study Group trial, 981
- metastatic, sequential use of endocrine therapy and chemotherapy in the treatment of: effects on survival, 111
- metastatic, tamoxifen therapy in premenopausal patients with, 787
- phase II trial of vindesine in the treatment of, 1001
- refractory advanced, vinblastine given as a continuous 5-day infusion in the treatment of, 279
- refractory, effectiveness of intermediate-dose methotrexate and high-dose 5-FU as sequential combination chemotherapy in the treatment of, 829
- refractory, minimal single-agent activity of maytansine in: a Southwest Oncology Group study, 675
- salvage treatment of patients relapsing after adjuvant chemotherapy for, 269
- stage IV, antiestrogen-induced remissions in premenopausal women with: effects on ovarian function, 779
- cervical
- advanced, BOMP (bleomycin, vincristine, mitomycin C, and *cis*-diamminedichloroplatinum(II)) in the treatment of, 1005
- doxorubicin, cyclophosphamide, and 5-FU in the treatment of, 549
- far-advanced, mitomycin C and bleomycin in the treatment of: a Southwest Oncology Group pilot study, 1139
- colon
- metastatic adenocarcinoma, phase II evaluation of PALA in the treatment of, 339
- metastatic, effectiveness of intermediate-dose methotrexate and high-dose 5-FU as primary therapy in the treatment of, 829
- colorectal
- advanced metastatic, phase III study of ICRF-159 versus 5-FU in the treatment of, 1047
- advanced, phase II evaluation of AMSA in the treatment of, 1149
- advanced, phase II evaluation of PALA in the treatment of, 349
- advanced, phase II study of fluorodopan in the treatment of, 697
- advanced, triazinate, ICRF-159, 5-FU, and methyl-CCNU in the treatment of, 1143
- metastatic, Baker's antifol combined with 5-FU and methyl-CCNU in the treatment of: a Southwest Oncology Group study (protocol 7764), 247
- metastatic human, lack of clinical therapeutic synergism between cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) in, 311
- esophageal, *cis*-diamminedichloroplatinum(II) in the treatment of, 709
- gastric, effects of chemotherapy with mitomycin C and 5-FU on pancreatic functions in patients with, 1151
- germ-cell, mediastinal, complete remission of, with the combination of *cis*-diamminedichloroplatinum(II), bleomycin, and vinblastine, 319
- head and neck
- advanced, phase II trial of vindesine in the treatment of, 1141
- advanced squamous cell, combination chemotherapy in the treatment of, 187
- previously treated squamous cell, phase II study of fluorouracil in the treatment of, 713
- lung
- advanced adenocarcinoma, phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) in the treatment of, 925
- advanced, phase II clinical trial of high-dose *cis*-diamminedichloroplatinum(II) with fluid- and mannitol-induced diuresis in the treatment of, 1241
- extensive adenocarcinoma and large cell undifferentiated, combination chemotherapy with 5-FU, vincristine, and mitomycin C in the treatment of, 1241
- extensive non-small cell, single-agent and combination chemotherapy for, 685
- metastatic, phase II evaluation of triazinate in the treatment of, 1057
- non-small cell, combination chemotherapy with bleomycin, doxorubicin, methotrexate, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of, 717
- non-small cell, doxorubicin, *cis*-diamminedichloroplatinum(II), and *Corynebacterium parvum* in the treatment of, 1367
- non-small cell, high-dose methotrexate in the treatment of: an Eastern Cooperative Oncology Group study, 1017
- non-small cell, phase II evaluation of AMSA in the treatment of, 345
- non-small cell, phase II evaluation of PALA in the treatment of, 705
- phase II evaluation of AMSA in the treatment of, 1383
- small cell, CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine in the treatment of, 997
- small cell, results of whole-brain irradiation for metastases from, 957
- small cell undifferentiated, update of recent results, 539
- squamous cell, a role of *cis*-diamminedichloroplatinum(II) in the treatment of, 87
- stage III non-small cell, high-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of: a randomized trial, 1131

lymphoma

advanced cutaneous T-cell, combination chemotherapy (vincristine, doxorubicin, bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone) in the treatment of, 1371

advanced diffuse histiocytic, treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy, 649

advanced non-Hodgkin's, phase II trial of AMSA in the treatment of, 1157

advanced, phase II study of maytansine in the treatment of: an Eastern Cooperative Oncology Group pilot study, 1115

Burkitt's, tumor lysis following malignant hyperthermia, 327

localized diffuse histiocytic, curative radiotherapy for, 175

malignant, ifosfamide, methotrexate, and vincristine combined as secondary treatment for patients with, 933

malignant, VM-26 combined with doxorubicin, bleomycin, and prednisone as a secondary treatment of, 335

non-Hodgkin's, *cis*-diamminedichloroplatinum(II) with and without ICRF-159 in the treatment of, 301

non-Hodgkin's, VP-16-213 combined with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of, 1135

phase II trial of vindesine in the treatment of, 1001

refractory malignant, randomized clinical trial comparing two dose regimens of ICRF-159 in the treatment of, 1355

melanoma

disseminated cutaneous malignant, combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine: 3 years' followup, 143

disseminated malignant, phase II study of maytansine and chlorozotocin in the treatment of, 721

disseminated malignant, phase II study of tamoxifen in the treatment of, 199

disseminated, randomized trial of chlorpromazine, caffeine, and methyl-CCNU in the treatment of, 151

malignant, estrogen and progesterone receptors and tamoxifen in, 819

malignant, phase II trial of vindesine in the treatment of, 179

metastatic malignant, DTIC in the treatment of: a simplified dose schedule, 1123

metastatic malignant, procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of, 139

metastatic malignant, tamoxifen in the treatment of, 171

metastatic, pilot study of vinblastine combined with bleomycin in the treatment of, 133

multiple myeloma, comparison of two combination chemotherapy regimens for treatment of: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone, 73

neuroblastoma

human, in vitro and in vivo preclinical chemotherapy studies of, 975

human, variability in DNA distributions of, after cyclophosphamide, 1275

osteosarcoma

metastatic, high-dose methotrexate with leucovorin rescue used alone and in combination for, 11

primary, high-dose methotrexate with leucovorin rescue used alone and in combination for, 11

ovarian

active third-line chemotherapy with weekly *cis*-diamminedichloroplatinum(II) in: a preliminary report, 1379

advanced, *cis*-diamminedichloroplatinum(II) in the treatment of, 1147

advanced, hexamethylmelamine, cyclophosphamide, methotrexate, and 5-FU in the treatment of, in patients with and without previous treatment, 323

pancreatic

advanced adenocarcinoma, long-term survival in patients with, 1391

phase II study of L-asparaginase in the treatment of, 1359

prostate, refractory metastatic, tamoxifen in the treatment of, 813

rectum, metastatic adenocarcinoma, phase II evaluation of PALA in the treatment of, 339

renal cell

advanced, methotrexate and citrovorum factor used alone and in combination for, 41

advanced, phase II study of tamoxifen in the treatment of, 343

metastatic, ifosfamide and mesnum with and without irradiation in the treatment of, 1103

metastatic, phase II trial of AMSA in the treatment of, 1009

metastatic, phase II trial of Baker's antifol in the treatment of: a Southwest Oncology Group study, 1387

sarcoma

advanced, cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) in the treatment of, 93

advanced, phase II evaluation of AMSA in the treatment of, 1129

advanced, phase II study in: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) (CAP), 655

advanced, results of the Royal Marsden Hospital Second Soft Tissue Sarcoma Schedule (STS II) chemotherapy regimen in the management of, 689

osteogenic, longitudinal studies of cellular immunity of patients with, during chemimmunotherapy, 589

osteogenic, pulmonary function tests during adjuvant lung irradiation for, 701

squamous cell

advanced recurrent, doxorubicin combined with cyclophosphamide in the treatment of, 1363

bleomycin, vincristine, and mitomycin C with or without methotrexate in the treatment of, 943

testicular

alone and in combination in the treatment of, 1077
disseminated nonseminomatous, sequential combination chemotherapy with vinblastine plus bleomycin doxorubicin plus *cis*-diamminedichloroplatinum(II) in the treatment of, 599

metastatic, probable cure of, treated with sequential therapy (vinblastine and bleomycin followed by *cis*-diamminedichloroplatinum[II], actinomycin D, and vincristine), 553

prognostic factors in: an approach to identification, 487

stage III, vinblastine, intermittent bleomycin, and single-dose *cis*-diamminedichloroplatinum(II) in the management of, 331

staging: a proposed clinical-surgical schema, 669

transitional cell

metastatic, of the urinary tract, combination chemotherapy with cyclophosphamide, doxorubicin, and bleomycin in the treatment of, 1011

of the urinary tract, phase II study of 5-FU and adriamycin in the treatment of, 161

vaginal, doxorubicin, cyclophosphamide, and 5-FU in the treatment of, 549

vulvar, advanced or recurrent, squamous cell, bleomycin alone or combined with mitomycin C in the treatment of, 639

CAP (cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(III)), randomized trial, versus pyrazofurin in a phase II study of advanced sarcoma, 655

Cardiomyopathy *see* Adverse effects, man

Cardiotoxicity *see* Adverse effects, animals; Adverse effects, man

Catheter, right atrial, use of for prolonged iv support in cancer patients, 243

CCNU

cause of variability in activity of samples of, against P388 leukemia in vivo, 987

combined with melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with procarbazine and vincristine in the treatment of disseminated cutaneous malignant melanoma: 3 years' followup, 143

combined with procarbazine and vincristine (PCV 3), modified, in the treatment of malignant brain tumors, 237

combined with procarbazine, vincristine, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma, 139

and doxorubicin, compared to CCNU, doxorubicin, vincristine, and procarbazine in the treatment of small cell bronchogenic cancer, 997

Cell culture studies

amygdalin (Laetrile), effect on clonogenic cells from human myeloid leukemia lines and normal human marrow, 105

inhibition by selected anticancer agents of the development of primary cell-mediated immunity against

allogeneic tumor cells, 211

Cell kinetics

effect of doxorubicin on, of 13762 rat mammary tumors and implications for therapy, 293

epidermal, in hairless mice after bleomycin: perturbations after multiple doses, 1039

Cervical cancer *see* Cancer, cervical

Chlorzotocin

cholestatic jaundice associated with, 1235

combined with maytansine, phase II study of, in the treatment of disseminated malignant melanoma, 721

Chlorpromazine, combined with caffeine and methyl-CCNU in the treatment of disseminated melanoma, 151

Cholestatic jaundice *see* Adverse effects, man

CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), advanced diffuse histiocytic lymphoma treatment with, without maintenance therapy, 649

Cisplatin *see* *cis*-Diamminedichloroplatinum(II)

Citrovorum factor, and methotrexate used alone and in combination chemotherapy for advanced renal cell carcinoma, 41

Clinical cancer

animal models of cancer immunotherapy: questions of relevance, 481

application of restricted sequential design in, 399

basic design considerations, 411

clinical considerations in the design of, 367

critical definitions and criteria for evaluation, 469

designing for nonparametric Bayesian survival analysis using historical controls, 503

design of phase II clinical trials in cancer using decision theory, 519

Designs for Clinical Cancer Research, Proceedings of the Symposium on, 363-538

designs to optimize combined-modality therapy and selection and verification of prognostic factors, 497

evaluation of toxicity: clinical issues, 457

evaluation of toxicity: statistical considerations, 463

operative procedures: is standardization feasible or necessary, 419

patient heterogeneity in, 405

perspective of the clinician, 537

pilot studies and new agent programs of the Eastern Cooperative Oncology Group, 525

in psychosocial medicine: methodologic and statistical considerations: assessing measurement techniques in psychosocial oncology, 451

in psychosocial medicine: methodologic and statistical considerations: assessing reliability with equal-appearing interval scales, 445

in psychosocial medicine: methodologic and statistical considerations: introduction, 441

quality assurance programs in, 425

research logic of radiation oncology in combined modality therapy, 473

selection of prognostic factors, 499

sequential, in cancer research, 393

summary views: a statistician's perspective, 533

use of new biologic agents in clinical immunotherapy, 435

- use of prognostic factors in analysis of historical control studies, 373
- use of prognostic factors in improving the design and efficiency of, in childhood leukemia: a Children's Cancer Study Group report, 381
- CMF (cyclophosphamide, methotrexate, and 5-FU)**, versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635
- CMFH (cyclophosphamide, methotrexate, 5-FU, and hydroxyurea)**, versus high-dose cyclophosphamide in the treatment of stage III non-small cell lung cancer: a randomized trial, 1131
- Colon cancer** *see* Cancer, colon
- Colorectal cancer** *see* Cancer, colorectal
- 7-Con-O-methylnogazol (7-OMEN)**
- and aclacinomycin, failure to decrease cardiac guanylate cyclase activity, 1127
 - activity of the anthracycline agent (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia, 727
- Corynebacterium parvum***
- combined with doxorubicin and *cis*-diamminedichloroplatinum(II) in the treatment of non-small cell lung cancer, 1367
 - combined with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157
 - enhancement of the antitumor activity of, by appropriate adjustment of dose and schedules, 915
- Cyclophosphamide**
- combined with adriamycin and high-dose methotrexate with leucovorin rescue in the treatment of measurable primary or metastatic osteosarcoma, 11
 - combined with adriamycin and vincristine and either levamisole immunotherapy or placebo in the treatment of advanced breast cancer, 65
 - combined with doxorubicin and bleomycin in the treatment of metastatic transitional cell carcinoma of the urinary tract, 1001
 - combined with doxorubicin and *cis*-diamminedichloroplatinum(II) (CAP) versus pyrazofurin, randomized trial: phase II study of advanced sarcoma, 655
 - combined with doxorubicin and 5-FU in the treatment of carcinoma of the cervix or vagina, 549
 - combined with doxorubicin in the treatment of advanced recurrent squamous cell carcinoma, 1363
 - combined with doxorubicin, vincristine, and prednisone (CHOP) in the treatment of advanced diffuse histiocytic lymphoma, without maintenance therapy, 649
 - combined with 5-FU, adriamycin, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157
 - combined with hexamethylmelamine, methotrexate, and 5-FU in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323
 - combined with methotrexate and 5-FU (CMF) versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635
 - combined with methyl-CCNU and prednisone versus melphalan and prednisone in the treatment of multiple myeloma, 73
 - combined with procarbazine, vincristine, and CCNU (POCC) in the treatment of metastatic malignant melanoma, 139
 - combined with triazinate, doxorubicin, and *cis*-diamminedichloroplatinum(II), phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925
 - combined with vincristine, adriamycin, and DTIC (CYVADIC) in the treatment of advanced sarcomas, 93
 - combined with vincristine and actinomycin D followed by doxorubicin and methotrexate in the treatment of advanced sarcoma, 689
 - combined with VP-16-213, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135
 - and doxorubicin and *cis*-diamminedichloroplatinum(II), lack of clinical therapeutic synergism between, in metastatic human colorectal carcinoma, 311
 - high-dose, versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial, 1131
 - plasma half-life and urinary excretion of, in children, 1061
 - with prednisone, 5-FU, methotrexate, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111
 - variability in DNA distributions of human neuroblastomas after, 1275
- CYVADIC (cyclophosphamide, vincristine, doxorubicin, and DTIC)**, combination chemotherapy for the treatment of advanced sarcomas, 93
- D**
- Danazol**, in the treatment of advanced breast cancer, 1073
- 3-Deazauridine**, phase I study of, in adults with solid tumors, 1295
- cis*-Diamminedichloroplatinum(II) (cisplatin)**
- alone and in combination in the treatment of testicular and other malignancies, 1077
 - combined with bleomycin and vinblastine in the treatment of mediastinal germ-cell tumors: complete remission of, 319
 - combined with bleomycin, doxorubicin, and methotrexate (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717
 - combined with bleomycin, vincristine, and mitomycin C (BOMP) in the treatment of advanced cervical cancer, 1005
 - combined with cyclophosphamide and doxorubicin (CAP) versus pyrazofurin, randomized trial: phase II study of advanced sarcoma, 655

combined with cyclophosphamide and doxorubicin, lack of clinical therapeutic synergism between, in metastatic human colorectal carcinoma, 311

combined with doxorubicin and *Corynebacterium parvum* in the treatment of non-small cell lung cancer, 1367

combined with triazinate, cyclophosphamide, and doxorubicin, phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925

and doxorubicin, sequential combination chemotherapy with vinblastine and bleomycin in disseminated non-seminomatous testicular cancer, 599

high-dose, with fluid- and mannitol-induced diuresis in the treatment of advanced lung cancer: phase II clinical trial, 1341

infiltration, cellulitis and fibrosis due to, 1162

nephrotoxicity of, as measured by urinary β -glucuronidase, 1083

nerve conduction studies in patients treated with: a preliminary report, 1119

phase I study of, administered as a constant 5-day infusion, 905

quantitative changes in, speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results, 123

renal handling of, 1223

a role of, in the treatment of squamous cell lung cancer, 87

selective inhibition of the nephrotoxicity of, by WR-2721 without altering its antitumor properties, 57

single-dose, combined with vinblastine and intermittent bleomycin in the management of stage III testicular cancer, 331

toxicity and antitumor activity, effect of sodium thiosulfate on, in L1210 leukemia, 611

in the treatment of advanced ovarian cancer, 1147

in the treatment of esophageal carcinoma, 709

weekly, active third-line chemotherapy in ovarian carcinoma: a preliminary report, 1379

with and without ICRF-159 in the treatment of non-Hodgkin's lymphoma, 301

Dianhydrogalactitol, and neural tumors: as in vitro, in vivo preclinical evaluation, 1287

Diglycoaldehyde (Inox)

phase II evaluation of, in the treatment of children with acute leukemia: a Children's Cancer Study Group report, 625

in the treatment of advanced adult acute leukemia: a Southwest Oncology Group study, 985

Dimethylhydrazine, -induced intestinal tumors, indomethacin treatment of rats with, 1323

DON (6-diazo-5-oxo-norleucine), phase I study of, 1247

Doxorubicin *see* Adriamycin

DTIC

combined with cyclophosphamide, vincristine, and adriamycin (CYVADIC) in the treatment of advanced sarcomas, 93

photosensitivity reaction following DTIC administration: report of two cases, 725

in the treatment of metastatic malignant melanoma: a simplified dose schedule, 1123

Dyskinesia, respiratory *see* Adverse effects, man

E

Emesis *see* Adverse effects, man

4'-Epi-doxorubicin, studies on the comparative distribution and biliary excretion of, with doxorubicin, in mice and rats, 897

Esophageal cancer *see* Cancer, esophageal

F

Fluorodopan, phase II study of, in the treatment of advanced colorectal cancer, 697

Fluoxymesterone, in the treatment of advanced breast cancer: a controlled clinical trial, 117

Ftorafur, phase II study of, in previously treated squamous cell cancers of the head and neck, 713

5-FU (5-fluorouracil)

combined with adriamycin, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157

combined with adriamycin, phase II study of, in the treatment of transitional cell carcinoma of the urinary tract, 161

combined with Baker's antifol and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group study (protocol 7764), 247

combined with cyclophosphamide and methotrexate (CMF) versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with doxorubicin and cyclophosphamide in the treatment of carcinoma of the cervix or vagina, 549

combined with hexamethylmelamine, cyclophosphamide, and methotrexate in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323

combined with mitomycin C, effects of chemotherapy with, on pancreatic functions in patients with gastric cancer, 1151

combined with thymidine, clinical pharmacologic effects of, 1169

combined with triazinate, ICRF-159, and methyl-CCNU in the treatment of advanced colorectal cancer, 1143

combined with vincristine and mitomycin C in the treatment of extensive adenocarcinoma of the lung, 1241

combined with vincristine, doxorubicin, bleomycin, methotrexate, leucovorin factor, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371

high-dose, and intermediate-dose methotrexate, effectiveness of, as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon, 829

intra-arterial infusion of, review of responses, 31

with prednisone, cyclophosphamide, methotrexate, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111

versus ICRF-159, phase III study of, in the treatment of advanced metastatic colorectal carcinoma, 1047

G

Gastric cancer *see* Cancer, gastric

Gentamicin, and irradiation, effect of, on the toxicity of high-dose methotrexate in rats, 989

Germ-cell cancer *see* Cancer, germ-cell

H

Head and neck cancer *see* Cancer, head and neck

Hepatic artery chemotherapy, radionuclide angiography to predict response to, 1217

Hepatic necrosis *see* Adverse effects, man

Hepatotoxicity *see* Adverse effects, man

Hexamethylmelamine

combined with cyclophosphamide, methotrexate, and 5-FU in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323
respiratory dyskinesia associated with, 355

HCFU (1-hexylcarbamoyl-5-fluorouracil), phase I study of, administered orally: an HCFU clinical study group report, 861

1-Hexylcarbamoyl-5-fluorouracil *see* HCFU

Hycanthone, hepatotoxicity of, in patients with metastatic breast cancer, 929

Hydrocortisone, combined with vincristine, doxorubicin, bleomycin, methotrexate, leucovorin factor, and 5-FU in the treatment of advanced cutaneous T-cell lymphomas, 1371

9-Hydroxyellipticine, and 2-methyl-9-hydroxyellipticinium acetate, metabolism and disposition studies of, in animals, 879

7-Hydroxymethotrexate, and methotrexate: serum level monitoring by high-pressure liquid chromatography, 165

Hydroxyurea

combined with cyclophosphamide and 5-FU versus high-dose cyclophosphamide in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized study, 1131

infusion, synchronization of L1210 leukemia with, and the effect of subsequent pulse dose chemotherapy, 81

Hypernephroma, metastatic, phase II trial of AMSA in the treatment of, 183

Hyperthermia

local, distribution of doxorubicin in mice under conditions of, which improve systemic drug therapy, 203
malignant, Burkitt's lymphoma: tumor lysis following, 327

I

ICRF-159

combined with cis-diamminedichloroplatinum(II) in the treatment of non-Hodgkin's lymphoma, 301

combined with triazinate, 5-FU, and methyl-CCNU in the treatment of advanced colorectal cancer, 1143
pharmacokinetics of, in the cerebrospinal fluid of sub-human primates, 734

randomized clinical trial comparing two dose regimens of, in refractory malignant lymphomas, 1355

versus 5-FU, phase III study of, in the treatment of advanced metastatic colorectal carcinoma, 1047

preclinical toxicologic evaluation of, in dogs, 1211

Ifosfamide

combined with doxorubicin in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study, 869

combined with mesnum with and without irradiation, in the treatment of renal cancer, 1103

combined with methotrexate and vincristine as secondary treatment for patients with malignant lymphoma, 933

Immunotherapy

levamisole, and polychemotherapy in advanced breast cancer, 65

longitudinal studies of cellular immunity of patients with osteogenic sarcoma during, 589

IMPY

clinical pharmacology of, by radioimmunoassay, 1253
clinical toxic effects of, with relevant pharmacokinetic parameters, 251

phase I clinical trial of, 1153

preclinical toxicologic study of, in mice, dogs, and monkeys, 1031

Indomethacin, treatment of rats with dimethylhydrazine-induced intestinal tumors, 1323

Inox *see* Diglycoaldehyde

L

Lactate dehydrogenase virus, infection of murine tumors: no effect on response to chemotherapy, 1161

Laetrile (amygdalin)

effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow, 105
trials as an example: ethics and designs, 363

Leucovorin

factor, combined with vincristine, doxorubicin, bleomycin, methotrexate, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371

rescue, leukoencephalopathy following high-dose iv methotrexate chemotherapy with, 1261

rescue, with high-dose methotrexate alone or in combination with adriamycin and cyclophosphamide in the treatment of measurable primary or metastatic osteosarcoma, 11

Leukemia

acute

adult advanced, diglycoaldehyde in the treatment of: a Southwest Oncology Group study, 985
 adult, previously treated, doxorubicin and ifosfamide in the treatment of: a Southwest Oncology Group pilot study, 869
 childhood, phase II evaluation of diglycoaldehyde (Inox) in, a Children's Cancer Study Group report, 625
 lymphocytic, childhood, use of prognostic factors in improving the design and efficiency of clinical trials in: a Children's Cancer Study Group report, 381
 refractory, sequential combination of methotrexate and L-asparaginase in the treatment of, 939
 treatment of, during pregnancy: presentation of nine cases, 679

Levamisole, immunotherapy, and polychemotherapy in advanced breast cancer, 65

Lewis lung cancer see Tumor systems, animals

L1210 leukemia see Tumor systems, animals

Lung cancer see Cancer, lung

Lymphoma see Cancer, lymphoma

M

Maytansine

combined with chlorozotocin, phase II study of, in the treatment of disseminated malignant melanoma, 721
 minimal single-agent activity of, in refractory breast cancer: a Southwest Oncology Group study, 675
 phase II study of, in the treatment of advanced lymphomas: an Eastern Cooperative Oncology Group pilot study, 1115
 response to, in a patient with malignant thymoma, 193

Melanoma see Cancer, melanoma

Melphalan

combined with CCNU, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635
 combined with doxorubicin and vincristine in the treatment of advanced breast cancer, 1015
 combined with prednisone versus methyl-CCNU, cyclophosphamide, and prednisone in the treatment of multiple myeloma, 73
 distribution and elimination of, in rats and monkeys and distribution in tumors of mice bearing L1210 or P388 leukemias sensitive and resistant to this agent, 643
 the first 25 years, 559
 intra-arterial infusion of, review of responses, 31
 oral, anaphylaxis due to, 731

6-Mercaptopurine, selective protection of cells from, by adenosine: biochemical approaches to the enhancement of antitumor drug selectivity, 1347

Mesnum, combined with ifosfamide with and without irradiation, in the treatment of renal cancer, 1103

Methotrexate

and L-asparaginase, sequential combination of, in the treatment of refractory acute leukemia, 939

and citrovorum factor used alone and in combination chemotherapy for advanced renal cell carcinoma, 41
 combined with bleomycin, doxorubicin, and *cis*-diamminedichloroplatinum(II) (BAMP) in the treatment of non-small cell bronchogenic carcinoma, 717

combined with CCNU, melphalan, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with cyclophosphamide and 5-FU (CMF) versus CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer in postmenopausal women, 635

combined with cyclophosphamide, 5-FU, and hydroxyurea (CMFH) versus high-dose cyclophosphamide in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial, 1131

combined with 5-FU, adriamycin, cyclophosphamide, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine in the treatment of metastatic breast cancer, 157

combined with hexamethylmelamine, cyclophosphamide, and 5-FU in the treatment of advanced ovarian carcinoma in patients with and without previous treatment, 323

combined with ifosfamide and vincristine as secondary treatment for patients with malignant lymphoma, 933

combined with vincristine, doxorubicin, bleomycin, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371
 and doxorubicin, given after combination of vincristine, actinomycin D, and cyclophosphamide in the treatment of advanced sarcoma, 689

high-dose, effect of gentamicin and irradiation on the toxicity of, in rats, 989

high-dose iv, leukoencephalopathy following, with leucovorin rescue, 1261

high-dose, phase II study of, in the treatment of non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study, 1017

high-dose, with leucovorin rescue, used alone and in combination for measurable primary or metastatic osteosarcoma, 11

and 7-hydroxymethotrexate: serum level monitoring by high-performance liquid chromatography, 165

intermediate-dose, and high-dose 5-FU, effectiveness of, as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon, 829

intra-arterial infusion of, review of responses, 31

with prednisone, cyclophosphamide, 5-FU, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111

Methyl-CCNU

combined with Baker's antifol and 5-FU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group study (protocol 7764), 247

combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma, 73

- combined with triazinate, ICRF-159, and 5-FU in the treatment of advanced colorectal cancer, 1143
- given alone or combined with chlorpromazine and caffeine in the treatment of disseminated melanoma, 151
- 2-Methyl-9-hydroxyellipticinium acetate**, and 9-hydroxyellipticine, metabolism and disposition studies of, in animals, 879
- Metoprine**, phase I trial of, in patients with advanced cancer, 951
- Metronidazole**, high-dose: pharmacokinetics and bioavailability using an iv preparation and application of its use as a radiosensitizer, 1087
- β 2-Microglobulin**, urinary, increased after cancer chemotherapy, 581
- Misonidazole**
- effect of hepatic microsomal enzyme inducers on the metabolism of, in rats, 275
 - effect of, on human granulopoietic stem cells, 1097
 - the 2-nitroimidazole, skin rashes associated with the administration of, 263
 - and phenytoin: possible metabolic interaction, 155
 - phenytoin sodium-induced alterations in the pharmacokinetics of, in the dog, 360
- Mitomycin C**
- combined with bleomycin and vincristine with or without methotrexate in the treatment of squamous cell carcinoma, 943
 - combined with bleomycin in the treatment of advanced or recurrent squamous cell carcinoma of the vulva, 639
 - combined with bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study, 1139
 - combined with bleomycin, vincristine, and *cis*-diamminedichloroplatinum(II) (BOMP) in the treatment of advanced cervical cancer, 1005
 - combined with 5-FU and vincristine in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung, 1241
 - combined with 5-FU, effects of chemotherapy with, on pancreatic functions in patients with gastric cancer, 1151
 - topical therapy, phase I-II study of, in the treatment of low-grade, low-stage transitional cell carcinoma of the bladder: an interim report, 225
- Multiple myeloma** *see* Cancer, multiple myeloma

N

- Nabilone**, and prochlorperazine, double-blind comparison of the antiemetic effects of, on chemotherapy-induced emesis, 219
- Nephrotoxicity** *see* Adverse effects, animals; Adverse effects, man
- Nerve conduction studies**, in patients treated with *cis*-diamminedichloroplatinum(II), 1119
- Neuroblastoma** *see* Cancer, neuroblastoma
- Neurotoxicity** *see* Adverse effects, animals

O

- 7-OMEN** *see* 7-Con-O-methylnogaro
- Osteosarcoma** *see* Cancer, osteosarcoma
- Ovarian cancer** *see* Cancer, ovarian

P

PALA

- initial clinical study with, in patients with advanced cancer, 617
 - peripheral leukocytes as indicators of the enzymatic effects of, on human L-aspartate transcarbamoylase activity, 967
 - phase I clinical study of, 285, 1301
 - phase I trial of, 1067
 - phase II evaluation of, in the treatment of advanced colorectal carcinoma, 349
 - phase II evaluation of, in the treatment of metastatic adenocarcinoma of the colon or rectum, 339
 - phase II evaluation of, in the treatment of non-small cell carcinoma of the lung, 705
- Pancreatic cancer** *see* Cancer, pancreatic
- PCV 3 (procabazine, CCNU, and vincristine)**, modified, in the treatment of malignant brain tumors, 237
- Pentamethylmelamine**
- early clinical trial of a 1-day intermittent schedule for, 993
 - phase I study of, 1319
 - phase I trial of, in patients with previous treated malignancies, 1335
 - a sensitive and specific assay for, in plasma: applicability to clinical studies, 99
- Pepleomycin**, and tallsomycin A, relative pulmonary toxicity and antitumor effects of two new bleomycin analogs in mice bearing Lewis lung carcinoma and B16 melanoma, 659
- Pericarditis** *see* Adverse effects, man
- Peritoneovenous shunt**, complications of, for malignant ascites, 305
- Pharmacokinetics**
- and bioavailability using an iv preparation and application of high-dose methotrexate's use as a radiosensitizer, 1087
 - clinical toxic effects of IMPY with relevant pharmacokinetic parameters, 251
 - early phase, of doxorubicin in plasma of cancer patients during single- or multiple-drug therapy, 845
 - of ICRF-187 in the cerebrospinal fluid of subhuman primates, 734
 - intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses, 31
 - of misonidazole in the dog, phenytoin sodium-induced alterations in the, 360
 - studies on the metabolism and, of tamoxifen in normal volunteers, 761
 - of vinblastine-loaded platelets utilized in the treatment of platelet-phagocytizing tumors, 1227

Phase I studies

- of AMSA by a weekly iv dose schedule, 53
- of *cis*-diamminedichloroplatinum(II) administered as a constant 5-day infusion, 905
- clinical study, of PALA, 285
- of 3-deazauridine in the treatment of adults with solid tumors, 1295
- of DON, 1247
- of HCFU (a new antitumor drug), administered orally: an HCFU clinical study group report, 861
- of IMPY, 1153
- of metoprine in patients with advanced cancer, 951
- of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: an interim report, 225
- of PALA, 1067, 1301
- of pentamethylmelamine, 1319
- of pentamethylmelamine in patients with previously treated malignancies, 1335
- and preliminary phase II observations of high-dose intermittent 6-thioguanine, 1109
- of spirogermanium, 1051

Phase II studies

- abbreviated, of thalcarpine, 1389
- in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) (CAP), 655
- of AMSA in the treatment of advanced colorectal cancer, 1149
- of AMSA in the treatment of advanced non-Hodgkin's lymphoma, 1157
- of AMSA in the treatment of advanced sarcoma, 1129
- of AMSA in the treatment of metastatic hypernephroma, 183
- of AMSA in the treatment of metastatic lung cancer, 1383
- of AMSA in the treatment of metastatic renal cell carcinoma, 1009
- of AMSA in the treatment of non-small cell lung cancer, 345
- of L-asparaginase in the treatment of pancreatic carcinoma, 1359
- of Baker's antifol in the treatment of metastatic renal cell carcinoma: a Southwest Oncology Group study, 1387
- of the combination of triazinate, cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung, 925
- of diglycoaldehyde (Inox) in children with acute leukemia: a Children's Cancer Study Group report, 625
- evaluation of agents in current use in the treatment of brain tumors, 1179
- of fluorodopan in the treatment of advanced colorectal cancer, 697
- of florafur in the treatment of previously treated squamous cell cancers of the head and neck, 713
- of 5-FU and adriamycin in transitional cell carcinoma of the urinary tract, 161
- of high-dose *cis*-diamminedichloroplatinum(II) with fluid- and mannitol-induced diuresis in the treatment

- of advanced lung cancer, 1341
- of high-dose methotrexate in the treatment of non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study, 1017
- of maytansine and chlorozotocin in the treatment of disseminated malignant melanoma, 721
- of maytansine in the treatment of advanced lymphomas: an Eastern Cooperative Oncology Group pilot study, 1115
- of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: an interim report, 225
- of PALA in the treatment of advanced colorectal carcinoma, 349
- of PALA in the treatment of metastatic adenocarcinoma of the colon or rectum, 339
- of PALA in the treatment of non-small cell carcinoma of the lung, 705
- preliminary, and phase I observations of high-dose intermittent 6-thioguanine, 1109
- of tamoxifen in the treatment of advanced renal cell carcinoma, 343
- of tamoxifen in the treatment of disseminated malignant melanoma, 199
- of 6-thioguanine in the treatment of metastatic breast cancer, 191
- of triazinate in the treatment of metastatic lung cancer, 1057
- use of a clinical tumor panel and overview of current resources and studies, 1
- of vindesine in the treatment of advanced head and neck cancer, 1141
- of vindesine in the treatment of advanced breast cancer, 693
- of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors, 1001
- of vindesine in the treatment of malignant melanoma, 179
- of VM-26 in the treatment of adult malignancies, 147

Phase III studies

- evaluation of agents in current use in the treatment of brain tumors, 1179
- of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma, 1047

L-Phenylalanine mustard (L-PAM) *see* Melphalan

Phenytoin, and misonidazole: possible metabolic interaction, 155

Photosensitivity *see* Adverse effects, man

Piperazinedione, extravasation, severe skin necrosis produced by, 1392

P388 leukemia *see* Tumor systems, animals

POCC (procarbazine, vincristine, CCNU, and cyclophosphamide), in the treatment of metastatic malignant melanoma, 139

Prednisone

- combined with CCNU, melphalan, and methotrexate (CAMP) versus cyclophosphamide, methotrexate, and 5-FU (CMF) in the treatment of advanced breast cancer in postmenopausal women, 635
- combined with cyclophosphamide, doxorubicin, and vincristine (CHOP) in the treatment of advanced dif-

- fused histiocytic lymphoma, without maintenance therapy, 649
- combined with melphalan versus methyl-CCNU, cyclophosphamide, and prednisone in the treatment of multiple myeloma, 73
- combined with methyl-CCNU and cyclophosphamide versus melphalan and prednisone in the treatment of multiple myeloma, 73
- combined with VM-26, doxorubicin, and bleomycin as a secondary treatment of malignant lymphoma, 335
- combined with VP-16-213, cyclophosphamide, doxorubicin, and vincristine in the treatment of non-Hodgkin's lymphomas, 1135
- with cyclophosphamide, 5-FU, methotrexate, and vincristine, used sequentially with endocrine therapy in the treatment of metastatic breast cancer: effects on survival, 111
- Price-Hill regimen** (vincristine, bleomycin, methotrexate, hydrocortisone, 5-FU, and leucovorin), in the treatment of advanced squamous cell carcinoma of the head and neck, 187
- Procarbazine**
- and CCNU, doxorubicin, and vincristine, compared to CCNU and doxorubicin in the treatment of small cell bronchogenic cancer, 997
- combined with CCNU and vincristine in the treatment of disseminated cutaneous malignant melanoma: 3 years' followup, 143
- combined with CCNU and vincristine (PCV 3), modified, in the treatment of malignant brain tumors, 237
- combined with vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma, 139
- Prochlorperazine**, and nabilone, double-blind comparison of the antiemetic effects of, on chemotherapy-induced emesis, 219
- Prostatic cancer** *see* Cancer, prostatic
- Pseudomonas vaccine**, combined with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, and *Corynebacterium parvum* in the treatment of metastatic breast cancer, 157
- Pyrazofurin**, randomized trial of, versus combination of cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II) (CAP): phase II study in advanced sarcoma, 655
- R**
- Radiation therapy**
- curative, for localized diffuse histiocytic lymphoma, 175
- and gentamicin, effect of, on the toxicity of high-dose methotrexate in rats, 989
- treatment of metastatic renal cancer with ifosfamide and mesnum with and without, 1103
- whole-brain, results of, for metastases from small cell carcinoma of the lung, 957
- Radioimmunoassay**, clinical pharmacology of IMPY by, 1253
- Radionuclide angiography**, to predict response to hepatic artery chemotherapy, 1217
- 13762 Rat mammary tumor** *see* Tumor systems, animals
- Rectal cancer** *see* Cancer, rectal
- Renal cell cancer** *see* Cancer, renal cell
- Ricin**, combined with doxorubicin in the treatment of L1210 mouse leukemia, 1375
- S**
- Sarcoma** *see* Cancer, sarcoma
- Selenium**, and vitamin E protection, evaluation of, against chronic doxorubicin toxicity in rabbits, 315
- Sodium thiosulfate**, effect of, on *cis*-diamminedichloroplatinum(II) toxicity and antitumor activity in L1210 leukemia, 611
- Spirogermanium**
- phase I clinical trial of, 1051
- toxicity of, in mice and dogs after iv or im administration, 1207
- Spirohydantoin mustard**, recovery from potentially lethal damage induced by, on 9L cells in vitro, 889
- Squamous cell cancer** *see* Cancer, squamous cell
- T**
- Tallysomycin A**, and pepleomycin, relative pulmonary toxicity and antitumor effects of two new bleomycin analogs in mice bearing Lewis lung carcinoma and B16 melanoma, 659
- Tamoxifen**
- antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function, 779
- clinical pharmacology of, in patients with breast cancer: comparison of traditional and loading-dose schedules, 765
- estrogen and progesterone receptors and, in malignant melanoma, 819
- estrogen-receptor binding and biologic activity of, and its metabolites, 741
- estrogen receptors and antiestrogen therapy in selected human solid tumors, 797
- an overview of recent studies in the field of oncology, 775
- pharmacology of, in laboratory animals, 745
- phase II study of, in the treatment of advanced renal cell carcinoma, 343
- phase II study of, in the treatment of disseminated malignant melanoma, 199
- studies on the metabolism and pharmacokinetics of, in normal volunteers, 761
- therapy in premenopausal patients with metastatic breast cancer, 787
- in the treatment of advanced breast cancer: a controlled clinical trial, 117
- in the treatment of advanced endometrial adenocarcinoma, 805
- in the treatment of metastatic malignant melanoma, 171

in the treatment of refractory metastatic carcinoma of the prostate, 813
 use of, in advanced male breast cancer, 801
Testicular cancer *see* Cancer, testicular
Thalidomide, abbreviated phase II trial of, 1389
6-Thioguanine
 high-dose intermittent, phase I and preliminary phase II observations of, 1109
 phase II trial of, in the treatment of metastatic breast cancer, 191
 selective protection of cells from, by adenosine: biochemical approaches to the enhancement of antitumor drug selectivity, 1347
Thiopropine, pharmacologic and toxicologic evaluation of: a proposed nontoxic inducer of reverse transformation, 837
Thymidine
 arrest and synchrony of cellular growth in vivo, 1307
 combined with 5-FU, clinical pharmacologic effects of, 1169
Thymoma, malignant, response to maytansine in a patient with, 193
Transitional cell cancer *see* Cancer, transitional cell
Triazine
 combined with cyclophosphamide, doxorubicin, and *cis*-diamminedichloroplatinum(II), phase II evaluation of, in the treatment of advanced adenocarcinoma of the lung, 925
 combined with ICRF-159, 5-FU, and methyl-CCNU in the treatment of advanced colorectal cancer, 1143
 phase II evaluation of, in the treatment of metastatic lung cancer, 1057
Tumor systems, animals
 B16 melanoma, relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A in, 659
 Lewis lung carcinoma
 effect of microbial fractions and vehicle on the survival of mice bearing, 1329
 relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A in, 659
 L1210 leukemia
 activity of the anthracycline agent, 7-con-O-methyl-nogarol (7-OMEN), administered orally to mice bearing, 727
 combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo, 231
 distribution and elimination of melphalan in rats and monkeys and distribution in tumors of mice bearing L1210 leukemia sensitive and resistant to this agent, 643
 effect of sodium thiosulfate on *cis*-diamminedichloroplatinum(II) toxicity and antitumor activity in, 611
 strongly synergistic combination of doxorubicin and ricin in, 1375
 synchronization of, with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy, 81

P388 leukemia
 activity of the anthracycline agent, 7-con-O-methyl-nogarol (7-OMEN), administered orally to mice bearing, 727
 cause of variability in activity samples of CCNU against, in vivo, 987
 distribution and elimination of melphalan in rats and monkeys and distribution in tumors of mice bearing P388 leukemia sensitive and resistant to this agent, 643
 13762 rat mammary tumor, effect of doxorubicin on the cell kinetics of, and implications for therapy, 293

U

Urinary β -glucuronidase, nephrotoxicity of *cis*-diamminedichloroplatinum(II) as measured by, 1083

V

Vaginal cancer *see* Cancer, vaginal

Vinblastine

and bleomycin, sequential combination chemotherapy with doxorubicin and *cis*-diamminedichloroplatinum(II) in disseminated nonseminomatous testicular cancer, 599
 combined with bleomycin and followed sequentially by *cis*-diamminedichloroplatinum(II), actinomycin D, and vincristine in the treatment of metastatic testicular cancer, 553
 combined with bleomycin, coronary artery disease after treatment with, 1159
 combined with bleomycin in the treatment of metastatic melanoma, 133
 combined with *cis*-diamminedichloroplatinum(II) and bleomycin in the treatment of mediastinal germ-cell tumors: complete remission of, 319
 combined with intermittent bleomycin and single-dose *cis*-diamminedichloroplatinum(II) in the management of stage III testicular cancer, 331
 given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer, 279
 -loaded platelets, pharmacokinetics of, utilized in the treatment of platelet-phagocytizing tumors, 1227

Vincristine

and CCNU, doxorubicin, and procarbazine, compared to CCNU and doxorubicin in the treatment of small cell bronchogenic cancer, 997
 combined with actinomycin D and cyclophosphamide followed by doxorubicin and methotrexate in the treatment of advanced sarcoma, 689
 combined with adriamycin and cyclophosphamide and either levamisole immunotherapy or placebo in the treatment of advanced breast cancer, 65
 combined with bleomycin and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma, 943

combined with bleomycin, mitomycin C, and *cis*-diamminedichloroplatinum(II) (BOMP) in the treatment of advanced cervical cancer, 1005

combined with CCNU and procarbazine in the treatment of disseminated cutaneous malignant melanoma: 3 years' followup, 143

combined with cyclophosphamide, adriamycin, and DTIC (CYVADIC) in the treatment of advanced sarcomas, 98

combined with cyclophosphamide, doxorubicin, and prednisone (CHOP) in the treatment of advanced diffuse histiocytic lymphoma, without maintenance therapy, 649

combined with doxorubicin, bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone in the treatment of advanced cutaneous T-cell lymphomas, 1371

combined with 5-FU and mitomycin C in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung, 1241

combined with ifosfamide and methotrexate as secondary treatment for patients with malignant lymphoma, 983

combined with melphalan and doxorubicin in the treatment of advanced breast cancer, 1015

combined with procarbazine and CCNU (PCV 3), modified in the treatment of malignant brain tumors, 237

combined with procarbazine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma, 139

combined with VP-16-213, cyclophosphamide, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135

-induced orthostatic hypotension: a prospective clinical study, 359

with prednisone, cyclophosphamide, 5-FU, and methotrexate, used sequentially with endocrine therapy in the treatment of metastatic breast cancer, 111

Vindesine

initial clinical study with: tolerance to weekly iv bolus and 24-hour infusion, 25

phase II evaluation of, in the treatment of breast cancer, 693

phase II trial of, in the treatment of advanced head and neck cancer, 1141

phase II trial of, in the treatment of malignant melanoma, 179

Vitamin E, and selenium protection, evaluation of, against chronic doxorubicin toxicity in rabbits, 315

VM-26

combined with doxorubicin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma, 335

phase II study of, in adult malignancies, 147

VP-16-213, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas, 1135

Vulvar cancer *see* Cancer, vulvar

W

WR-2721, selective inhibition of the nephrotoxicity of *cis*-diamminedichloroplatinum(II) by, without altering its antitumor properties, 57



Author Index

A

Abbruzzi R, 873
Adam HK, 761
Ahmann DL, 199, 721
Ahmed M, 353
Aisner J, 1009, 1335, 1392
Alavi J, 343
Albo V, 381
Allalunis MJ, 1097
Allen JC, 1261
Allen KE, 745
Al-Sarraf M, 161, 713
Amadori S, 939
Arbes H, 41
Ardalan B, 967
Argy WP, 1083
Armitage JO, 649
Aroney RS, 1011
Astry CL, 915
Aviles A, 679

B

Bach BK, 801
Bachur N, 123
Baker LH, 93, 1139
Baker SR, 943
Banerjee TK, 191
Barbieri B, 873
Barlogie B, 1295
Barlow JJ, 549, 1379
Barnett M, 765
Bateman JR, 47, 981
Battersby LA, 775, 801
Baumgartner G, 41
Becherini JO, 73
Beck TM, 725
Begg CB, 1355
Belt RJ, 1235
Benedict WF, 975, 1275
Benigni A, 873
Benjamin RS, 93, 629, 1253, 1295
Bennett JM, 525
Bennett WM, 921
Berenzweig M, 717, 1143
Beretta G, 353
Bernheim J, 1341
Bertrand M, 889
Beutler E, 243

Bhakoo HS, 819
Bhatia PS, 1235
Bickers JN, 869
Bisel HF, 721
Bjornsson S, 1367
Blom J, 1135
Bloomfield CD, 175, 1135
Blum RH, 1067
Blumenschein GR, 157, 279
Boden JA, 1161
Bodey GP, Sr, 93, 157, 285, 629, 909, 929, 933, 1253, 1295
Bondue H, 1341
Bonnell S, 1363
Bonnet JD, 247
Bono VH, Jr, 1
Bosl GJ, 331, 487
Bottomley R, 93, 869
Bowles D, 11
Boyd MR, 99
Bracken RB, 225
Braun DW, Jr, 219
Braunschweiler PG, 293
Brenner DE, 1392
Breslow N, 497
Brodovsky H, 343, 813
Broggini M, 845, 897
Brotman R, 425
Browman GP, 231
Brown BW, Jr, 499
Brown NS, 1253
Brown RK, 559, 643
Brunner KW, 335
Bryant BM, 689
Bukowski RM, 1387
Bull FE, 943
Bull JM, 1015
Burgess AM, Jr, 285
Burgess MA, 909, 1295
Burgess ME, 93
Buzdar AU, 157, 373
Byar D, 469
Byhardt RW, 957

C

Cabanillas F, 933
Cable R, 1227
Calanog A, 1005

Calman KC, 797
 Camacho FJ, 179, 693
 Campbell M, 713
 Canellos GP, 1067, 1147
 Canfell C, 165
 Caracandas J, 1367
 Carcelen A, 701
 Carceres E, 701
 Carlson M, 819
 Carmo-Pereira J, 143
 Carr B, 1283
 Carroll DS, 349, 1149
 Carter CJ, 629
 Carter SK, 367
 Casadio M, 1131
 Casper ES, 345, 705, 1247, 1301
 Cassady JR, 963
 Catalano RB, 1047
 Cavagnaro F, 73
 Chahinian P, 193
 Chan RC, 989
 Charles LM, Jr, 1
 Chen H-SG, 31
 Cheng E, 1141
 Chester A, 1001
 Child JA, 581
 Chillar RK, 243
 Chism VT, 1329
 Chiuten DF, 1, 1335
 Chlebowski RT, 47, 981
 Cho E-S, 257
 Chung HS, 975
 Claudon DB, 419
 Clausen OPF, 1039
 Coakley AJ, 732
 Coccia P, 381
 Cohen MH, 151
 Colombo T, 897
 Coltman C, Jr, 356
 Come SE, 1147, 1217
 Comis R, 1227
 Connors TA, 1160
 Coombes RC, 1073
 Cooney DA, 967
 Corder MP, 301, 649, 1389
 Cormier WJ, 655
 Costa RO, 143
 Cowan DH, 1123
 Cowan JD, 1119
 Cox DR, 533
 Cox JD, 957
 Creagan ET, 87, 199, 311, 721, 925, 993, 1057, 1383
 Crooke ST, 225
 Crowley J, 191
 Culo F, 57
 Currie VE, 693, 951
 Cysyk RL, 203

D

Dalley DN, 1011
 Danon YL, 1275

Dat-Xuong N, 879
 Davey F, 1227
 Davis HL, Jr, 507
 Davis S, 685, 709
 Davis TE, 191
 Dearmaley D, 1073
 DeCosse JJ, 419
 Deen DF, 889
 DeFuria MD, 225
 De Jager R, 1341
 De Laurentis C, 939
 Denefrio JM, 193, 1153
 Denes AE, 1109
 DeSimone P, 1359
 DeWys W, 669
 DiBella NJ, 359
 Dick FR, 649
 Dierckx P, 1341
 Diggs CH, 339
 Dillman RO, 139
 Di Marco AR, 1131
 Dische S, 263
 Dix CJ, 745
 Doeden D, 1061
 Dombernowsky P, 635
 Donegan WL, 419
 Donelli MG, 845, 873, 897
 D'Orsi CJ, 1217
 Drapkin R, 1367
 Dunbar J, 549
 Duncan G, 643
 Dutcher JS, 99

E

Eagan RT, 87, 655, 925, 993, 1057, 1383
 Earhart RH, 943
 Edelson RL, 1371
 Edmonson JH, 655, 721
 Edwards MS, 237, 1179
 Egan EM, 1307
 Egorin M, 123
 Ehrke MJ, 211
 Elashoff R, 411
 Ellington OB, 243
 Elliott TE, 649, 1389
 Ellison NM, 363
 Elson D, 356
 Engstrom PF, 1047
 Ensminger WD, 943, 1217, 1307
 Eppolito C, 211
 Epstein J, 1347
 Epstein MB, 1275
 Erik-Johnsson J, 639
 Erlichman C, 967
 Ersboll J, 1135
 Ervin TJ, 1067
 Ettinger DS, 1017
 Evans WE, 11
 Ewing SL, 997

F

Fabian C, 765
 Fahey JL, 243
 Falkson G, 191, 358
 Fantone JC, 1023
 Farbstein M, 243
 Feig S, 1077
 Feldstein ML, 445
 Ferrans VJ, 315
 Ferremans W, 1341
 Finklestein J, 625
 Fisher WB, 327
 Fitzpatrick A, 1227
 Fleming GHA, 243
 Fleming JJ, 581
 Fleming TR, 87, 1057
 Fodstad Ø, 1375
 Fong K-LL, 1253
 Ford HT, 1073
 Fosså SD, 1103
 Fraile RJ, 1139
 Fraley EE, 331, 487
 Frei E, III, 1307
 Freireich EJ, 285, 629, 1253
 Frenning DH, 997, 1159
 Frizzera G, 175
 Frytak S, 37, 721, 925, 1057, 1383
 Fujii M, 1151
 Furner RL, 559

G

Gangji D, 155
 Garrett S, 1109
 Gauci L, 193
 Gazet JC, 1073
 Gehan EA, 373
 George SL, 393
 Ginsberg S, 1227
 Glatstein E, 539
 Gleiser CA, 989
 Glick JH, 343, 813, 1115, 1355
 Glicksman AS, 425
 Golbey RB, 705, 1129
 Goldberg RS, 1319
 Golde DW, 105
 Goldhirsch A, 335
 Goldman A, 487
 Goodnight JE, 1077
 Gormley P, 123, 734
 Gouyette A, 879
 Gralla RJ, 219, 345, 349, 705, 1129, 1301
 Gram TE, 659
 Green AA, 11
 Green MR, 139
 Green SJ, 199
 Greenberg DB, 355
 Greenspan EM, 25

Greenwald EH, 1005
 Griffin JP, 1319
 Griffiths CT, 1147
 Gross JF, 31
 Gutterman JU, 157

H

Haas CD, 1235
 Hacker MP, 837
 Haq MM, 909, 929
 Hahn RG, 655, 721
 Hajdu E, 1287
 Hanjani P, 1363
 Hammond D, 381, 625
 Hansen MM, 1135
 Harkrader RJ, 1347
 Harris D, 343, 813, 1115
 Hart NE, 725
 Hart RD, 617
 Harvey HA, 731
 Havsteen H, 635
 Heilbrun LK, 247
 Heinz R, 41
 Helson J-L, 1287
 Helson L, 1287
 Henderson ES, 1367
 Henriques E, 143
 Henry MC, 855, 1031, 1207, 1211
 Hersh EM, 157
 Herson J, 463
 Hewlett JS, 869
 Higby D, 1367
 Higgins GR, 625
 Hilgers R, 1139
 Hill DL, 643
 Ho DHW, 629, 1253
 Holland JF, 25, 617, 1169
 Hoogstraten B, 537
 Horten B, 1261
 Hortobagyi GN, 157, 279
 Horton C, 139
 Horton J, 1115
 Hoshino T, 889
 Hoth D, 1051
 Houghton A, 345, 705
 Houghton DC, 921
 Howarth C, 11
 Howell SB, 611
 Hueser J, 47
 Humphreys J, 1073
 Hussein K, 869

I

Ihde DC, 539
 Ingle JN, 87, 199, 925, 1057, 1383
 Irwin LE, 981
 Isaacs H, Jr, 975

J

Jackson RC, 1347
 Jacobs C, 1223
 Jacobs EM, 47, 669
 Jaffrey IS, 193, 1391
 Jait C, 73
 Jayaram HN, 967
 Jensen-Akula MS, 1
 Jiang N-S, 199
 Johnson DE, 225
 Johnson K, 487
 Johnson RK, 1067
 Jones NF, 419
 Jones RB, 99
 Jones SE, 269, 1001
 Jordan VC, 745
 Jørgensen J, 1135
 Jortner BS, 257
 Joyce RP, 1119

K

Kalman SM, 1223
 Kaplan BH, 717, 1005
 Kaplan R, 1359
 Kaplan WD, 1217
 Karakousis CP, 819
 Karon M, 381
 Kaye SB, 1161
 Keating MJ, 279
 Kelly DR, 997
 Kelsen DP, 345, 705
 Kemeny NE, 349, 1149
 Kemp JV, 761
 Kempin SJ, 951
 Kenis Y, 1341
 Kennedy BJ, 331, 487, 997, 1159
 Kensler TW, 967
 Kessler W, 709
 Kies MS, 1119
 King GW, 251
 Klag M, 1227
 Klastersky J, 1341
 Klefström P, 65
 Klein L, 1109
 Klotz J, 507
 Knebel K, 889
 Kochi M, 21
 Koeffler HP, 105
 Kogelnik HD, 263
 Komaki R, 957
 Kovach JS, 993
 Koyama Ya., 861
 Koyama Yo., 861
 Koziol D, 1087
 Krakoff IH, 837, 1319
 Krivit W, 625, 1061
 Kuberka N, 1367

Kubota TT, 1
 Kufe DW, 1067, 1307
 Kuhn JA, 1083
 Kun LE, 957
 Kutas GJ, 1123
 Kvols LK, 87, 721, 925, 1057, 1383
 Kwong R, 331

L

Laing L, 797
 Lange PH, 331
 Larsson G, 639
 Laufman LR, 675
 Lawrence BV, 731
 Lazarus H, 231
 Leake RE, 797
 Lee CKK, 175
 Legha SS, 157, 909, 929
 Lehotay DC, 1127
 Leichman LP, 1139
 Leikin S, 381
 Leimert JT, 301, 649, 1389
 Lein JM, 73
 Lele S, 1379
 Lelli G, 1131
 Lenox-Smith I, 263
 Lenzhofer R, 41
 Le Pecq J-B, 879
 LeRoy AF, 123
 Lesnick GJ, 361
 Lessner HE, 1359
 Leventhal BG, 435
 Levey BA, 1127
 Levey GS, 1127
 Levi JA, 1011
 Levin DC, 1217
 Levin VA, 237, 1179
 Levine BS, 855, 1031, 1207, 1211
 Levitt SH, 175
 Lewis KP, 1162
 Libert P, 1341
 Libretti A, 845
 Lichtenfeld JL, 1335
 Liepman MK, 943
 Lippman ML, 1015
 Lipton A, 731
 Litterst CL, 208
 Livingston RB, 1241
 LoBuglio A, 1387
 Lo Gerfo P, 1371
 Lokich JJ, 305, 905
 Longeval E, 1341
 Loo TL, 279, 285
 Loose L, 915
 Lopez RE, 819
 Lovett JM, 1389
 Lowe L, 105
 Luckert PH, 1323
 Lynch G, 1149

M

Macbeth FR, 797
 Macdonald JS, 1051
 Magill GB, 1129, 1247
 Magin RL, 203
 Maguire LC, 301
 Mahesh Kumar AP, 11
 Mairese P, 1341
 Malspeis L, 251
 Mandel E, 1169
 Mandelli F, 939
 Mangioni C, 845
 Manni A, 111, 779
 Markus S, 1009
 Marsoni S, 845
 Marti JR, 285
 Martin DS, 1169
 Martini A, 897
 Martini N, 539
 Martino S, 161
 Mashiter K, 1073
 Matsumoto Y, 21
 McCormack JJ, 837
 McCracken JD, 675, 1387
 McCredie KD, 1295
 McGovren JP, 727
 McGregor D, 1235
 McMahan LJ, 1241
 McShan D, 425
 McSherry JW, 1319
 Meakin JW, 787
 Medina WD, 1162
 Megirian R, 915
 Mehta BM, 1261
 Meier CR, 599
 Memo R, 553
 Merrin CE, 225
 Meshad MW, 1067
 Metter GE, 1109
 Metz EN, 553
 Meyskens FL, Jr, 171
 Michel J, 1341
 Micheo EQ, 73
 Microcha CJ, 1061
 Mihich E, 211
 Miller DR, 381
 Miller HC, 225
 Miller TP, 1001, 1241
 Minna JD, 539
 Mittelman A, 697
 Mizutani T, 21
 Moayeri H, 697
 Mobbs BG, 787
 Mochizuki K, 21
 Moertel CG, 311
 Moisand C, 879
 Montgomery JA, 987
 Moore EC, 285
 Moore R, 819
 Morales M, 679

Moran M, 701
 Moran RE, 81
 Morasca L, 845
 Morgan DB, 581
 Morgan LR, 225
 Moriarty JK, Jr, 1083
 Morrison FS, 985
 Morrow GR, 451
 Moukhtar M, 1005
 Mouridsen HT, 635
 Muggia FM, 1, 539, 669
 Multhauf P, 507
 Murphy SG, 1329
 Murray GB, 355
 Musso A, 73
 Muzard G, 879
 Myers CP, 1275
 Myers RE, 787

N

Naeher C, 1367
 Nair KG, 697
 Nakajima E, 575
 Nakamura K, 575
 Nash AG, 1073
 Natale N, 845
 Natale RB, 345, 1301
 Nathanson L, 133
 Negendank W, 813
 Neidhart JA, 251, 553, 675
 Neijt JP, 323
 Nesbit M, 381
 Newell GR, 363
 Newman RA, 837
 Nicaise C, 1341
 Nichols WC, 925, 1057, 1383
 Nishigaki T, 575
 Nissen NI, 1135
 Niz J, 679
 Noriega L, 679
 Norman A, 1275
 Nystrom JS, 1017

O

O'Connell MJ, 311, 993, 1355
 Ohnuma T, 25, 617, 1169
 Oken MM, 1355
 Orsini F, 211
 Osoba D, 1123
 Oster MW, 187, 1371
 Ostrow S, 123
 Ottolenghi L, 845

P

Pacilli L, 939
 Padavic K, 813

Padgett C, 1153
 Pajak TF, 47
 Panasci LC, 1227
 Pandya MR, 191, 685
 Pannuti F, 1131
 Panther SK, 301
 Paoletti C, 879
 Papa G, 939
 Parapia L, 581
 Parker LM, 1147
 Paroly WS, 47
 Partington JP, 1087, 1097
 Pastore L, 921
 Pathre S, 1061
 Patterson JS, 761, 775, 801
 Paul AR, 1047
 Pavlovsky S, 73
 Pearson OH, 111, 779
 Pearson RW, 327
 Pedersen-Bjergaard J, 1135
 Perloff M, 361
 Pesando JM, 1147
 Piana E, 1131
 Piazza E, 845
 Pihl A, 1375
 Pileggi JE, 73
 Pimentel P, 143
 Pincus C, 629
 Pinedo HM, 319, 323
 Pirovino M, 335
 Piver MS, 549, 1379
 Pizzo PA, 1023
 Pizzolato M, 73
 Pizzuto J, 679
 Plunkett W, 285
 Polk G, 356
 Pollard M, 1323
 Poplack DG, 734
 Port CD, 855, 1031, 1207, 1211
 Powles TJ, 1073
 Pratt CB, 11
 Presant CA, 1109
 Pridun N, 41
 Priest J, 1061
 Pritchard KI, 787, 1123
 Pugh RP, 47, 981, 1387

Q

Qazi R, 1143
 Quirt IC, 1123

R

Raafat J, 187, 1371
 Rabin HR, 1087
 Rakowski TA, 1083
 Rambotti P, 685

Ransom JL, 11
 Ravez P, 1341
 Reinhold R, 305
 Reinstein LE, 425
 Reynolds R, 981
 Richman SP, 1329
 Riihimaki DU, 243
 Rivera G, 11
 Rivkin SE, 93
 Rizzardini M, 873
 Roboz J, 1169
 Rodriguez V, 933
 Rodzynek JJ, 1341
 Rogerson B, 1127
 Romero F, 679
 Roozendaal KJ, 323
 Rosen E, 1031, 1207, 1211
 Rosen F, 819
 Rosen G, 1261
 Rosenberg SA, 589
 Rosenthal S, 1115
 Rosowsky A, 1307
 Ross DA, 1347
 Roth JL, 1119
 Rozencweig M, 1
 Rozsa P, 1287
 Rubert M, 1227
 Rubery ED, 732
 Rubin J, 311, 993
 Rubin P, 473
 Rucker N, 975, 1275
 Rudolph A, 1227
 Ruiz E, 1127
 Russ J, 285
 Ryan DH, 869
 Ryden MJ, 981
 Ryssel HJ, 335

S

Sadée W, 165
 Saito Y, 21
 Salazar OM, 473
 Salimtschik M, 635
 Sallan SE, 963
 Salmon SE, 269
 Salmona M, 873
 Samaan NA, 909
 Samal B, 161
 Samson MK, 1139
 Sarna G, 1077
 Sather H, 381
 Saunders MI, 263
 Schein PS, 1051, 1083
 Scheulen ME, 599
 Schiffer LM, 293
 Schilcher RB, 599
 Schimberg TP, 237
 Schmale AH, 441
 Schmidt CG, 599

Schneider RJ, 53, 183
 Schoenfeld D, 151
 Schreiner GE, 1083
 Schüller J, 41
 Schulz JJ, 147
 Schutt AJ, 311
 Schwade JG, 155
 Scoltock M, 339
 Seager ML, 237
 Sealy R, 263
 Sears HF, 589
 Sedransk N, 419
 Seeber S, 599
 Seeger RC, 975, 1275
 Serrou B, 193
 Sessa C, 845
 Shanmugathasa M, 709
 Sharon M, 1087
 Shaw MT, 247, 985
 Shoemaker D, 275
 Siddiqi N, 1367
 Siddik ZH, 659
 Siegel MM, 975, 1275
 Siegel SE, 975
 Sikic BI, 659
 Silverman M, 305, 1153
 Silverstein MN, 1355
 Simon R, 405, 589
 Simonsen E, 639
 Simpson DP, 1283
 Sinkovics JG, 93
 Skinner DG, 1077
 Sklaroff RB, 1247
 Sladek NE, 1061
 Slater SR, 741
 Slavik M, 1051
 Slayton RE, 353
 Smith C, 243
 Smith CE, 725
 Smith EH, 1217
 Smith F, 1051
 Smith RB, 1077
 Smith TL, 373
 Smythe T, 1051
 Snel S, 635
 Soares N, 734
 Soloway MS, 225
 Sonntag RW, 335
 Sordillo PP, 345, 1129
 Speckhart VJ, 147
 Spector GB, 989
 Spiegel RJ, 1023
 Spoor RP, 915
 Spremulli E, 147
 Stanhope CR, 1139
 Stanley KE, 1017
 Staquet MJ, 519
 Stark J, 1147
 Staubus AE, 251
 Steele GD, Jr, 1217
 Steele N, 219

Sternson L, 765
 Stewart DJ, 1253, 1295
 Stolear JC, 1341
 Straus DJ, 1157
 Straus MJ, 81
 Strong JM, 155, 275
 Struyvenberg A, 323
 Stuckey WJ, 869, 985
 Suárez A, 73
 Suer RP, 327
 Suh K, 1367
 Sutherland DJA, 787
 Swenerton KD, 805
 Sylvester RJ, 519

T

Taetle R, 611
 Takeuchi S, 21
 Takvorian RW, 1217
 Talle K, 1103
 Tanaka M, 575
 Tashima CK, 279
 Tejada F, 701
 Theodorakis M, 1227
 Theologides A, 997
 Thigpen T, 93
 Thiriaux J, 1341
 Thompson EI, 399
 Thomson DB, 787
 Thorud E, 1039
 Tisman G, 829
 Tonnesen GL, 963
 Tormey DC, 191, 1015
 Torri S, 343
 Totsuka S, 575
 Townsend JJ, 237
 Tretton M, 1223
 Tribalto M, 939
 Triplett DA, 327
 Tropé C, 639
 Trowbridge AA, 985
 Trowbridge RC, 997
 Trujillo JE, 111
 Tschopp L, 335
 Tullis J, 305
 Turner AR, 1097
 Turner MA, 243
 Tyagi AK, 967

U

Upton D, 275
 Urtasun RC, 1087, 1097

V

Vaitkevicius VK, 1139
 Valdivieso M, 285, 1295

Valenstein S, 1359
 Van-Bac N, 879
 Van Echo DA, 339, 1009, 1335
 van Eys J, 989
 van Hoesel QGCM, 319
 van Lindert ACM, 323
 Van Ryzin J, 503
 Van Vleet JF, 315
 Varansi UR, 1283
 Vaughn C, 675
 Vendrik CPJ, 323
 Vial RH, 869
 Vietti TJ, 457
 Villani F, 353
 Vitale L, 381
 Voakes JB, 171
 Vogel CL, 1153
 Vogelzang NJ, 997, 1159
 Vogl SE, 717, 1005, 1143
 Von Hoff DD, 356, 734
 Vosika GJ, 997

W

Wakeling AE, 741
 Walker K, 1087
 Wallens WT, 1367
 Wampler GL, 147
 Wang Y-M, 989
 Warrell RP, Jr, 1157
 Waxman S, 1169
 Weerts D, 1341
 Wehling M, 123
 Wein A, 343, 813
 Weiner JM, 981
 Weiner MW, 1223
 Weiss DW, 481
 Weiss RB, 539
 Wendt AG, 269
 Westerberg H, 117
 Wheeler RH, 943

Whitacre M, 1335
 White RAS, 360
 Wiernik PH, 123, 339, 1009, 1335, 1392
 Wiesenfeld M, 301
 Wilson CB, 237, 1179
 Wilson HE, 247, 869
 Wiltshaw E, 689
 Wise H, 553
 Wiseman CL, 157
 Wiseman CW, 929
 Wittenberg BK, 133
 Wittes RE, 179, 693, 1141
 Wolfe LC, 963
 Wollner D, 717
 Wolter J, 151
 Woodcock TM, 53, 183, 1149
 Woolley PV, 1051
 Workman P, 360
 Wright DC, 237
 Wu SJG, 829

Y

Yagoda A, 183, 1301
 Yap B-S, 93, 1253
 Yap H-Y, 157, 279
 Young CW, 53, 179, 219, 693, 705, 951, 1141, 1157, 1247, 1301
 Young D, 251
 Yuhas JM, 57
 Yunis A, 1359

Z

Zaharia M, 701
 Zelen M, 525
 Zia PK, 243
 Zighelboim J, 1077
 Zimmerman HJ, 1023

